Baseimmune Ltd. has announced its strategic expansion into fibrosis, with a new fibrosis-focused pipeline led by a program for idiopathic pulmonary fibrosis (IPF).
Baseimmune Ltd. has raised $11.3 million through a series A to accelerate the development of its deep learning AI technology for predicting future pathogen mutations to generate a series of longer-lasting, multistrain vaccines.
Baseimmune Ltd. has closed $11.3 million (£9 million) in series A funding. The company uses proprietary, deep learning artificial intelligence (AI) to predict future pathogen mutations to generate novel vaccines.
